99 related articles for article (PubMed ID: 7750983)
1. Oxidants generated by the myeloperoxidase-halide system activate the fifth component of human complement, C5.
Vogt W; Hesse D
Immunobiology; 1994 Dec; 192(1-2):1-9. PubMed ID: 7750983
[TBL] [Abstract][Full Text] [Related]
2. Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes.
Vogt W
Immunobiology; 1996 Aug; 195(3):334-46. PubMed ID: 8877407
[TBL] [Abstract][Full Text] [Related]
3. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
4. Cleavage of the fifth component of complement and generation of a functionally active C5b6-like complex by human leukocyte elastase.
Vogt W
Immunobiology; 2000 Jan; 201(3-4):470-7. PubMed ID: 10776801
[TBL] [Abstract][Full Text] [Related]
5. Activation of the fifth component of human complement by oxygen-derived free radicals, and by methionine oxidizing agents: a comparison.
Vogt W; Hesse D
Immunobiology; 1992 Apr; 184(4-5):384-91. PubMed ID: 1592429
[TBL] [Abstract][Full Text] [Related]
6. Activation of the fifth component of human complement, C5, without cleavage, by methionine oxidizing agents.
Vogt W; Zimmermann B; Hesse D; Nolte R
Mol Immunol; 1992 Feb; 29(2):251-6. PubMed ID: 1542301
[TBL] [Abstract][Full Text] [Related]
7. The release of C5a in complement-activated serum does not require C6.
Biesecker G; Wagner JL; Hugli TE
J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
[TBL] [Abstract][Full Text] [Related]
8. Freeze-thaw activation of the complement attack phase: I. Separation of two steps in the formation of the active C--56 complex.
Dessauer A; Rother U; Rother K
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():75-81. PubMed ID: 6587745
[TBL] [Abstract][Full Text] [Related]
9. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
10. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
Stewart JL; Kolb WP; Sodetz JM
J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
[TBL] [Abstract][Full Text] [Related]
11. Generation of an activated form of human C5 (C5b-like C5) by oxygen radicals.
von Zabern WV; Hesse D; Nolte R; Haller Y
Immunol Lett; 1987 Feb; 14(3):209-15. PubMed ID: 3552970
[TBL] [Abstract][Full Text] [Related]
12. Functional properties of the asialo-fifth component of human complement.
Schultz DR; Arnold PI
J Immunol; 1990 Jul; 145(2):655-61. PubMed ID: 2114446
[TBL] [Abstract][Full Text] [Related]
13. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
[TBL] [Abstract][Full Text] [Related]
14. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
Hetland G; Bungum L
APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
[TBL] [Abstract][Full Text] [Related]
15. Terminal complement components play a role in the expression of C5a.
Gresham HD; Renfer L; Hammer CH; Frank MM
J Immunol; 1987 Feb; 138(3):838-41. PubMed ID: 3805718
[TBL] [Abstract][Full Text] [Related]
16. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
17. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
Balkarowa-Ständer J; Rother U; Rauterberg EW
J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
[TBL] [Abstract][Full Text] [Related]
18. Non-enzymic activation of the fifth component of human complement, by oxygen radicals. Some properties of the activation product, C5b-like C5.
Vogt W; Damerau B; von Zabern I; Nolte R; Brunahl D
Mol Immunol; 1989 Dec; 26(12):1133-42. PubMed ID: 2561180
[TBL] [Abstract][Full Text] [Related]
19. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
Brannen CL; Sodetz JM
Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
